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The high-throughput brain slice method is a precise and robust technique for estimating the overall uptake of drugs
into brain tissue through determination of the unbound volume of distribution in the brain (Vu,brain; ml·g brain
-1).
Vu,brain describes the relationship between the total drug concentration in the brain and the concentration of
unbound drug in the brain interstitial fluid, regardless of blood–brain barrier function. The brain slice method is more
physiologically based than the brain homogenate method with respect to the assessment of drug distribution in the
brain because the cell-cell interactions, pH gradients and active transport systems are all conserved. The method
provides information that is directly relevant to issues such as nonspecific binding to brain tissue, lysosomal trapping,
and active uptake into the cells. For these reasons, the brain slice method is recommended for estimation of
target-site pharmacokinetics in the early drug discovery process and fundamental pharmacological studies. This
article provides a detailed protocol for the rat and mouse brain slice methods, with the aim of enabling simple,
cost-effective profiling of compounds with diverse physicochemical properties. The procedure for assessing the
viability of the brain slices after the 5 h incubation period is also described. The results are interpreted for a set of
compounds covering a wide range of physicochemical properties and various pharmacological targets. Application
of the method for evaluating the unbound intracellular-to-extracellular concentration ratio (Kp,uu,cell) and the
unbound brain-to-plasma concentration ratio (Kp,uu,brain) is discussed.
Keywords: Brain slice method, Unbound volume of distribution in the brain, Neuropharmacokinetics, Drug
discovery, High-throughput screeningBackground
It is generally accepted that the cerebral concentration of
unbound drug is the main pharmacokinetic determinant
of CNS activity for neurotherapeutics [1-3]. Preliminary
assessment of the clinically relevant pharmacokinetic
parameters required for approximation of the unbound-
drug concentration in the brain interstitial fluid is thus
pivotal in guiding early drug discovery research [4]. Be-
cause of the cost and complexity of the methodology,
many of the available “gold standard” pharmacokinetic
methods are not appropriate for use in the early stages of
drug discovery. Consequently, there is an urgent need for
adequate high-throughput in vitro systems and methods
for CNS drug development programs.* Correspondence: mhu@farmbio.uu.se
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reproduction in any medium, provided the orThe implementation of the high-throughput equilib-
rium dialysis-based assay for estimation of the fraction
of unbound drug in the brain tissue (fu,brain), combined
with measurement of whole brain concentrations
in vivo, was groundbreaking for the field [5]. However,
homogenization of the brain as used in this method
changes the brain tissue binding properties, leading to
implicit errors in the readouts [6].
In contrast, the brain slice method has a more physio-
logical basis and has several benefits over the brain hom-
ogenate method. The brain slice preparation method
was implemented by Henry McIlwain and is now exten-
sively used in neurobiology, biophysics and quantitative
pharmacology [7-9]. It has the advantage of offering a
strongly regulated in vitro environment, while preserving
much of the complex cellular integrity, including cellular
barriers and intact circuitry, and as a result conserving
functionality – resulting in an in vitro environmentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Composition of the working aECF solution
Weight (g)/volume (ml)
Glucose 1.802 g
Milli-Q water* 600 ml
Stock aECF 100 ml
280 mM CaCl2 5 ml
400 mM Ascorbic acid 1 ml
pH (23°C) Adjust pH to 7.6 (up to 1.5 ml of 10 M NaOH)
Milli-Q water Adjust volume to 1000 ml
* should be dispensed the day before the experiment.
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homogenate method.
Several research groups have used the method to esti-
mate the uptake of exogenous compounds into the brain
[10-15]. Moreover, studies have investigated mechanistic
pharmacokinetic/pharmacodynamic links using brain
slice methodology [13,16].
Measurements obtained from in vivo microdialysis
have also been compared to those from the in vitro brain
slice and homogenate methods [17]. The reasonable cor-
respondence (within a 3-fold range) between the cere-
bral microdialysis and brain slice method results in this
study indicates that the brain slice method is the choice
of preference [17].
The brain slice method has recently been further
developed for high-throughput, making it more access-
ible for use by pharmaceutical companies [18]. It is
now a precise, robust technique for estimating the
overall uptake of drugs into brain tissue through deter-
mination of the unbound volume of distribution in the
brain (Vu,brain; ml·g brain
-1). Vu,brain describes the rela-
tionship between the total drug concentration in the
brain and the unbound-drug concentration in the brain
interstitial fluid, regardless of blood–brain barrier function.
The key assumption of the experiment is that, at equilib-
rium, the unbound-drug concentration in the brain slice
interstitial fluid (ISF) or extracellular fluid (ECF) is equal to
the drug concentration in the buffer in the beaker.
This article provides a detailed protocol for the rat and
mouse brain slice methods, with the aim of encouraging
simple, cost-effective profiling of compounds with diverse
physicochemical properties and unifying procedures




The protocols presented below are based on animal
experiments approved by the Animal Ethics Committee
of Uppsala, Sweden (C21/9 and C351/11). Drug-naïve male
Sprague–Dawley 250–300 g rats and Naval Medical Re-
search Institute (NMRI) 25–30 g mice were used (Taconic,
Lille Skensved, Denmark). The fresh brain slices can be
prepared from various strains of wild type and genetically
modified mice and rats, depending on the purpose of the
study and the respective laboratory traditions. The brain
slices could as well be genetically manipulated using meth-
ods such as viral infection [19], biolistics [20], etc.
Preparatory steps
Artificial extracellular fluid
To ensure maintenance of the brain slices in a healthy
state, the artificial settings should mimic the in vivo cellular
environment. The composition of artificial cerebrospinalfluid or extracellular fluid (aECF) is crucial. A large number
of formulations for these artificial fluids can be found in
the literature. In the experimental settings used in the stud-
ies underlying this paper, the HEPES-buffered aECF con-
tained 129 mM NaCl, 3 mM KCl, 1.4 mM CaCl2, 1.2 mM
MgSO4, 0.4 mM K2HPO4, 25 mM HEPES, 10 mM glucose
and 0.4 mM ascorbic acid [18]. Ascorbic acid is used as a
natural free-radical scavenger to protect the cell mem-
branes from lipid peroxidation and the brain slices from
swelling [21].
Prior to starting an experiment, a stock solution of
aECF (1290 mM NaCl, 30 mM KCl, 12 mM MgSO4,
4 mM K2HPO4, 250 mM HEPES) is prepared and stored
at room temperature. The 400 mM stock solution of as-
corbic acid should be stored at +4°C.
On the day before the experiment, 1 L of Milli-Q water
should be dispensed. On the day of experiment, this is used
to prepare the working aECF solution according to the for-
mulation (Table 1). The solution is then equilibrated with
100% oxygen for 15 minutes in an ice-water bath. The pH
of the aECF should be 7.6 at 23°C at the beginning of the
experiment and about 7.3 at 37°C directly after the 5 h in-
cubation. See Table 2 for a summary of the critical steps in
the brain slice experiment protocol.
Preparation of cassettes
This protocol allows simultaneous investigation of a
selection of up to ten compounds within the same
experiment, allowing coverage of a wide range of
physicochemical properties and various pharmaco-
logical targets in the same cassette.
When deciding on the compounds of each cassette,
the pKa values of the compounds should be taken into
account. Because high concentrations of weak bases can
increase the pH of the acidic intracellular compartments,
the extent of lysosomal trapping of a weak base could be
affected by the existence of another weak base. The inter-
action between two weak bases is mainly regulated by the
concentrations of the free compounds in the cassette and
their potency in increasing intralysosomal pH [22]. Conse-
quently, it is recommended that the final aECF concentra-
tion of each studied compound in the cassette should be
Table 2 Critical steps in the brain slice experiment
Experimental stages Critical steps
Preparatory steps Control the pH, osmolarity and
oxygenation of the aECF
Take into account the pKa values of the
compounds when selecting the drugs
to be investigated in one cassette
Do not take longer than 1 minute to
extract the brain
Keep cold-chain during the brain slicing
procedure
Preserve the brain slices in ice-cold
oxygenated aECF before starting the
incubation
Incubation Keep oxygenation, temperature and
stirring constant during the incubation
Preparation of the samples
for bioanalysis
Make sure all minor debris from the brain
slices has sedimented before taking the
aECF samples after the 5 h incubation
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compounds should not exceed 1 μM [18].
Each cassette of compounds is prepared individually,
ex tempore, in scintillation vials (20 ml glass vials with
screw lids; one vial per rat or mouse brain). Initially, the
required volume of stock drug solution is added to an
empty scintillation vial. To reduce possible toxic effects
of the solvents (methanol, acetonitrile, etc.) on the brain
slices, the solvents are evaporated under a gentle stream
of nitrogen before diluting the sample with aECF. When
using dimethyl sulfoxide (DMSO) to dissolve the com-
pounds, it is strongly recommended that the final con-
centration of DMSO is kept as low as possible (no higher
than 1%). Subsequently, 20 ml of ice-cold aECF, pre-
equilibrated with 100% oxygen, is added to each scintilla-
tion vial and ultrasonicated for 10 minutes to facilitate
the dissolution of the compounds. These ready-to-use
solutions are maintained at 37°C until incubation.
Preparation of slices
The glassware and tools are set up for the dissection
prior to preparing the brain slices. The vibrating blade
microtome (e.g. Leica VT1200 (Leica Microsystems
AB, Sweden)) is prepared for slicing and the chambers
are chilled.
Drug-naïve rats/mice are anesthetized with inhalation
anesthesia using 5% isoflurane. When deep anesthesia is
reached, up to 10 ml of blood (rats) is collected intracar-
dially. The animal is then decapitated and the skull quickly
opened. The isolated brain is immediately placed into
blank ice-cold aECF saturated with oxygen. In our experi-
ence, the brains should be sliced within 15–20 minutes of
harvesting to retain their viability. Slices from three rat/
mouse brains are generally equilibrated during the same
day with one cassette of drugs.The pre-chilled chamber of the vibratome is filled with
ice-cold oxygenated aECF just before use and is then
placed in the ice-filled tray of the vibratome.
It is advantageous to put one or two drops of cyano-
acrylate glue on the cutting platform one minute before
mounting the brain, to allow the glue to dry slightly.
Working quickly, the brain is placed on a chilled Petri
dish covered with filter paper. Using a #22 surgical
blade, a 3 mm piece is cut from the rostral area on a
coronal plane, leaving a piece of about 10 mm for subse-
quent slicing. A caudal cut is then made (Figure 1A).
The 10 mm piece of the brain is glued to the slicing
platform in a coronal position (Figure 1B), and the plat-
form is then positioned in the slicing chamber filled with
the blank ice-cold aECF. The razor blade (Gillette,
super-stainless) is then mounted and the clearance angle
is fixed at 21°. We use a motorized blade holder section-
ing speed of 0.8 mm/s with a 1 mm amplitude, in
0.05 mm steps.
After discarding the first one or two brain slices, 6 (rat
brain) or 10 (mouse brain) consecutive 300 μm brain
slices are cut on a coronal plane, starting approximately
1.7 mm anterior to the bregma (rostral striatum).
The 300 μm thickness provides good cell preservation
without compromising the diffusion of oxygen into the
core of the slice. The equilibration time during incuba-
tion is inversely related to the square of the brain slice
thickness [16].
The slices are moved, using a micro spatula, to the
brain slice storage beaker filled with oxygenated blank
aECF which is kept in an ice bucket before the incu-
bation. It is recommended that only brain slices with
intact edges be used for the experiment, to reduce the
amount of debris detaching from the brain tissue dur-
ing incubation.
The slicing platform should be scrubbed to remove
the brain and glue remnants, and the chamber refilled
with fresh ice-cold oxygenated aECF, before proceeding
with the next brain. The vibratome chambers should be
cleaned, disinfected and dried at the end of each experi-
mental day.
Incubation
The incubation-equilibration process is started by gently
transferring the 6 (rat) or 10 (mouse) brain slices from the
storage beaker (using a micro double-ended spatula) into
one 45 mm high, 80 mm diameter, flat-bottomed glass bea-
ker (Duran Group, VWR, Sweden) containing 15 ml (rat)
or 10 ml (mouse) of the aECF containing the selection
of drugs to be investigated (Figure 1C). The beaker is
then filled with humidified 100% oxygen over the aECF
and covered with a custom-fabricated lid (Figure 1D)
composed of a Teflon fluorinated ethylene-propylene
(FEP) film (50 Å, 12.7 μm thick; DuPont, Katco Ltd,
Figure 1 The main steps in the preparation of brain slices. A. Schematic representation of the cutting directions. B. Brain glued to the slicing
platform in a coronal position. C. Brain slices transferred into the 80 mm diameter, flat-bottomed glass beaker. D. Beaker covered by custom-
fabricated lid composed of a Teflon fluorinated ethylene-propylene film. E. Setup for the incubation-equilibration period.
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modifications [23]. A “blank” beaker is also incubated in
parallel to check stability of the compounds added into
the buffer.
The transparent Teflon FEP film is used in preference
to a glass lid because it is selectively permeable to gases
(e.g. oxygen) while remaining relatively impermeable to
water vapor. This significantly decreases evaporation
(allowing improved control of osmolarity and pH), thus
permitting the use of a non-humidified incubator.
Finally, the beaker is placed inside the small plastic
box in the incubated shaker (e.g. MaxQ4450 Thermo
Fisher Scientific, NinoLab, Sweden) for 5 h at 37°C
(Figure 1E). Control of the temperature by an external
thermometer is recommended. A rotation speed of
45 rpm and oxygen flow of about 75–80 ml per mi-
nute through a glass frit apparatus appear sufficient.
The pH of the aECF should be measured at 37°C im-
mediately after the 5 h incubation. A reduction of more
than 0.15 pH units over the 5 hours indicates more than
acceptable acidification of the buffer.
Preparation of the samples for bioanalysis
It is necessary to take several samples for bioanalysis
during the experiment:
I. aECF samples
a. for thermostability testing of the compounds studied
(sampled before and after incubation in aECF without
the brain slices)b. for measurement of Cbuffer – the final concentrations
of the unbound compounds in aECF (sampled at the
end of the 5 h incubation with the brain slices)
II.Brain slices samples
a. for measurement of Abrain – the amount of drug in t-
he brain slices (sampled at the end of the 5 h
incubation)
Procedural details for preparation of the aECF and
brain slice samples are given below.
I. aECF samples
a. Assessment of the thermostability of the compounds
provides valuable information and is recommended f-
or each drug selection tested. A 200 μl sample of aE-
CF is taken directly from the beaker at the beginning
of the study and at the end of 5 h incubation without
brain slices for analysis of initial and final concentra-
tions of the drugs in aECF. The aECF sample is trans-
ferred into an Eppendorf tube containing 200 μl
blank brain homogenate that has been prepared be-
forehand with 4 volumes of blank aECF. The brain h-
omogenate is included to prevent nonspecific binding
of drugs to the plastic as well as to match the matrix
of the slice homogenates, as required for the follow-
ing LC-MS-MS analysis.
b. Since the unbound drug concentration in the brain
slice interstitial fluid at equilibrium is taken to be
equal to the drug concentration in the aECF in the
beaker, the presence of any minor debris from the
Table 3 Brief description of assessment of viability of
brain slices based on the activity of released lactate
dehydrogenase
1. Preparation of Background absorbance control. Take 200 μl of aECF
buffer from the scintillation vial containing the drug cassette before
incubation and mix with 200 μl of blank aECF (store at +4°C pending
analysis)
2. Preparation of Low control. Take 200 μl of aECF buffer from the
beaker containing the drug cassette five minutes after transferring
the freshly prepared brain slices into the beaker and mix with 200 μl
of blank aECF buffer (store at +4°C pending analysis)
3. Preparation of Samples. Take 200 μl of aECF buffer from the beaker
containing the drug cassette and brain slices after 5 hours of
incubation and mix with 200 μl of blank aECF buffer (store at +4°C
pending analysis)
4. Preparation of High control. Place one (rat) or 3 (mouse) weighed brain
slices in an Eppendorf tube after 5 hours of incubation with the drug
cassette, and add 9 volumes (w/v) of 2% Triton X-100 solution in aECF.
Put Eppendorf tubes in ultrasound bath for 1 hour at +4°C. Then
incubate the tubes for 30 minutes in a water bath at 37°C. Centrifuge at
10000 rpm for 5 minutes at +4°C Take supernatant and store at +4°C
pending analysis
5. Preparation of the samples for analysis, see Table 4. Perform all tests
in triplicate Protect the plate from light after addition of freshly
prepared reaction mixture
6. Incubate the plate for up to 25 minutes at room temperature
7. Measure the absorbance of the samples at 492 nm (use 690 nm as a
reference wavelength)
Table 4 Preparation of samples for assessment of










Background 100 μl 100 μl
Low control 100 μl 100 μl
Sample 100 μl 100 μl
High control 100 μl 100 μl
* The reaction mixture should be prepared ex tempore according to the
manufacturer's instructions.
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after the 5 h incubation. To achieve this, the beaker
needs to sit still for 5 minutes after finishing the i-
ncubation before sampling the aECF. To sample, 2-
00 μl of the aECF is aspirated from just below the
surface (without wetting the tip before sampling) a-
nd dispensed into an Eppendorf tube containing the
200 μl of blank brain homogenate, as described in
Ia. It is recommended that duplicate samples of the
aECF be taken at this stage. Filtration of aECF, wh-
ich is recommended by several authors, is not suit-
able for drug distribution studies because of the
possible loss of the compounds in the filter.
II.Brain slice samples
a. After sampling the aECF, the brain slices in the aECF a-
re individually removed, dried on filter paper (about 30
s), weighed (~33 mg per rat brain slice and ~13 mg per
mouse brain slice) and homogenized separately in 9 vo-
lumes (w/v) of aECF with an ultrasonic processor (e.g.
VCX-130; Sonics, Chemical Instruments AB, Sweden).
The samples are then stored at −20°C pending bioana-
lysis (e.g. LC-MS-MS).
Assessment of viability of brain slices
The brain slices must remain viable during the experiment.
There are several methods of assessing viability based on
biochemical and/or electrophysiological parameters. In our
laboratory, the viability of the brain slices is assessed by
measuring the relative activity of released lactate dehydro-
genase (LDH) using a cytotoxicity detection kit [24]
according to the manufacturer's instructions (Roche
Diagnostics GmbH, Germany), with some modifications.
A brief description of the preparation of the main con-
trols and samples required for analysis is given in
Tables 3 and 4.
To calculate the viability of the brain slices (as a percent-
age) after the 5 h incubation-equilibration period, the fol-
lowing steps are taken for each experimental setup:
 Background absorbance control - provides informa-
tion about the background absorbance of the assay
medium (aECF). For this purpose, 200 μl sample of
aECF is taken at the beginning of the experiment fro-
m the scintillation vial and mixed with 200 μl blank
aECF. The obtained absorbance value is then sub-
tracted from all other values.
 Low control - provides information about the activ-
ity of LDH released from the brain slices as a result
of damage to the membranes caused by slicing the
brain. A 200 μl aECF sample is taken 5 minutes after
transferring the brain slices into the beaker for incu-
bation and is then mixed with 200 μl blank aECF. High control - provides information about the max-
imum possible activity of releasable LDH in the brain
slice. To achieve this, one rat or three mouse brain s-
lices are used after the 5 h incubation for each ex-
perimental setup. After drying the brain slice(s) on
filter paper and individually weighing them, 9 volum-
es (w/v) of 2% Triton X-100 solution in aECF is add-
ed. To facilitate the release of LDH from the brain
slice(s), the Eppendorf tube is placed in an ultra-
sound bath for one hour at +4°C followed by 30 min-
utes of incubation in a water bath at 37°C. The
supernatant obtained after centrifugation of the tube
for 5 minutes at 10,000 rpm and +4°C is stored at +-
4°C pending analysis (no longer than 5 days).
For preparation of the experimental samples (experi-
mental value), 200 μl of aECF sample is taken after the
Table 5 Checklist before starting the experiments
aECF Stock aECF
280 mM CaCl2
400 mM ascorbic acid
Dispensed the day before 1 L MQ water
Oxygen supply
pH meter








Glass- and lab-ware Petri dishes
45 mm high, 80 mm diameter, flat-bottomed
glass beakers
Custom-fabricated lids of Teflon FEP film for
beakers
Scintillation vials
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200 μl blank aECF. For evaluation of the effects of
changes in viability of the brain slices during the incuba-
tion, aECF samples can be taken at different time points
(after 1, 2, 3, etc. hours).
Once the absorbance of the control and experimental
samples has been obtained (Table 3) the relevant viabil-
ity (%) of the brain slices can be calculated according to
Equations 1 and 2:
Cytotoxicity %ð Þ ¼ experimental value low control
high control low control  100
ð1Þ
Viability %ð Þ ¼ 100% Cytotoxicity %ð Þ ð2Þ
In practice, it is recommended that 85-90% viability be
aimed for; however, a viability of around 60% provides
similar results according to our experience (data not
shown). Viability values lower than 50% after the 5 h incu-
bation period are associated with dramatic changes in the
estimation of Vu,brain, especially for weak bases and results
from the experiments should be discarded.
Estimation of Vu,brain
Bioanalytically determined drug concentrations in the
brain slices and the 5 h aECF samples are used to estimate
Vu,brain. It is critical to remember to scale back the obtained
concentrations (or areas under the concentration-time
peaks) to the undiluted buffer and brain slice concentra-
tions by multiplying by the dilution factors as appropriate.
The concentration in each brain slice sample is multiplied
by 10 to account for the dilution during preparation of the
homogenate. The concentration in aECF is multiplied by 2
to account for the dilution during 1:1 mixing of the aECF
sample with blank brain homogenate (in 4 volumes (w/v)
of aECF). The dilutions associated with protein precipita-
tion are not accounted for because they are the same for
all samples.
Vu,brain (ml · g brain
-1), as defined in Equation 3, is
equivalent to the ratio of the amount of drug in the brain
or brain slice (Abrain, nanomoles · gram brain
-1) to the
measured final aECF concentration (Cbuffer, micromoles
per liter) or unbound brain interstitial fluid concentra-
tion (Cu,brainISF) measured using cerebral microdialysis
technique:




Because of incomplete absorption of aECF by the
filter paper, the brain slices have a surrounding layer
of aECF, and it is important to measure the volume
of this layer (Vi, milliliters per gram of slice) and
compensate for this aECF buffer layer, i.e. (1-Vi) inEquation 4. Vi should be measured in a separate ex-
periment using [14C] inulin as described in Fridén
et al. [18]. Vi was reported to be 0.094 ml ∙g slice
-1
[18]. In view of this, Equation 3 can be reorganized
to obtain Vu,brain corrected for the remaining aECF
volume on the brain slice:
Vu;brain ¼
Abrain  V i _Cbuffer
Cbuffer _ 1 V ið Þ
ð4Þ
High-throughput screening capacity
Once the brain slice methodology is established in the
laboratory (Table 5), it can be used in a high-throughput
manner. One trained individual can perform up to four
experiments per day (using rats or mice). The method
allows up to 10 compounds to be tested simultaneously
(consultation with an analytical chemist is required). A
series of three experiments is enough to obtain consist-
ent results for one cassette.
Figure 2 A number of applications of Vu,brain for integrative pharmacology.
Table 6 Unbound volume of distribution in the brain
(Vu,brain) determined using Sprague–Dawley (SD) rat and
Naval Medical Research Institute (NMRI) mouse brain slices
Ion class Vu,brain ml·g brain
-1
SD rat NMRI mouse
Verapamil Base 46.6 (1.8) 47.3 (4.4)
Docetaxel Base 777 (217) 796 (177)
Oxycodone Base 4.20 (0.13)* 3.75 (0.22)
Digoxin Base 33.1 (6.0) 44.9 (5.7)
Gabapentin Zwitterion 4.49 (0.29) 4.22 (0.93)
Indomethacin Acid 14.1 (1.8) 12.0 (1.8)
Paroxetine Base 714 (72) 596 (97)
Thioridazine Base 2650 (232) 1930 (170)
Diazepam Neutral 17.8 (1.1) 17.1 (2.3)
* Data from Fridén et al., 2011 [6].
Data are reported as means (standard deviations).
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The high-throughput rat or mouse fresh brain slice
method is a powerful tool for estimating the intracereb-
ral distribution of diverse compounds in an in vitro
setup with preserved cellular barrier functionality. The
method allows the estimation not only of nonspecific
binding of compounds to the brain tissue but also of the
cellular accumulation of compounds through uptake
transporters, trapping in acidic intracellular compart-
ments (i.e. lysosomes), and active efflux from the cellular
membrane [6]. Consequently, the determination of more
physiological Vu,brain values using fresh brain slices in-
stead of brain homogenates permits more precise assess-
ment of Cu,brainISF (Figure 2) with reduced risk of
misrepresentation during subsequent evaluation of
exposure-target engagement relationships.
The estimated Vu,brain value can be put into context
by comparison with the physiological volume of brain
fluids, e.g. Vu,brain values higher than 0.8 ml · g brain
-1
(the volume of total brain fluids is 0.8 ml · g brain-1)
are interpreted as intracellular distribution of the drug
in question [4,18]. Values higher than this indicate that
proportionally more of the drug is intracellularly dis-
tributed, e.g. into lysosomes, and/or bound to parenchy-
mal components. A value lower than 0.8 ml · g brain-1
shows restricted distribution. The lowest volume pos-
sible in vivo is the brain interstitial fluid volume of
0.2 ml · g brain-1; however, in the slices, this is somewhat
higher because of damage to the surface layer of cells.Table 6 shows Vu,brain values of nine drugs covering a
wide range of physicochemical properties and pharma-
cological targets. Vu,brain has extensive variability with a
range from 3.75 to 2650 ml · g brain-1.
An additional very important aspect of drug discov-
ery is the ability to extrapolate the results to other
species. Recently, it has been shown that unbound
fraction of drug in brain homogenate value obtained
from the Wistar Han rat brain homogenate can be
used as a representative value for any preclinical spe-
cies and also humans [25]. The results in Table 6
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Vu,brain values between Sprague–Dawley rats and
NMRI mice. However, a more systematic investiga-
tion is desirable before the possibility of interchange-
able use of Vu,brain measurements can be supported
for translational studies.
It has been proposed by Fridén et al. [17] that
in vitro determination of Vu,brain in combination with
in vivo determination of the total brain-to-plasma con-
centration ratio (Kp,brain) and in vitro determination of
the fraction of unbound drug in plasma (fu,plasma)
would allow rapid evaluation of unbound brain-to-
plasma concentration ratio (Kp,uu,brain) (Figure 2).
Moreover, combining Vu,brain with fu,brain would allow es-
timation of the unbound intracellular-to-extracellular
concentration ratio (Kp,uu,cell). It is essential to emphasize
that, in terms of predicting Cu,brainISF or Kp,uu,brain, rank
ordering of compounds with respect to Vu,brain is futile,
since there is no causal relationship [4].
Complex evaluation of the abovementioned neurophar-
macokinetic parameters gives insight to drug distribution
in the brain. For instance, analogue of γ-aminobutyric
acid gabapentin has Kp,brain equal to 0.64 [26]. How-
ever, after correction of Kp,brain for brain tissue uptake
(using Vu,brain derived from the brain slice method)
and plasma protein binding (using fu,plasma) the BBB
net flux was estimated as a 0.14 meaning that only
14% of unbound drug in plasma is passing the BBB.
Moreover, after passing BBB gabapentin (substrate to
the large neutral amino acid transporter) tends to accu-
mulate in the cells as it could be judged from Kp,uu,cell
equal to 4.55 [6].
The brain slice method can also be used to identify
suitable positron emission tomography (PET) tracers,
which should have a low degree of nonspecific binding
(i.e. a low Vu,brain value) to obtain higher specificity for
their targets.
In summary, the brain slice method, used for assess-
ment of the volume of distribution of unbound drug in
the brain, is a useful tool for both drug discovery and
fundamental pharmacology research.
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